Strides Pharma Science Past Earnings Performance
Past criteria checks 0/6
Strides Pharma Science's earnings have been declining at an average annual rate of -50.1%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 5.9% per year.
Key information
-50.1%
Earnings growth rate
-50.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 5.9% |
| Return on equity | -8.7% |
| Net Margin | -3.9% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Strides Pharma Science makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 39,535 | -1,525 | 7,642 | 0 |
| 30 Sep 23 | 37,806 | -2,280 | 7,607 | 0 |
| 30 Jun 23 | 36,783 | -924 | 7,159 | 0 |
| 31 Mar 23 | 36,884 | -2,212 | 7,686 | 0 |
| 31 Dec 22 | 35,680 | -1,824 | 7,395 | 0 |
| 30 Sep 22 | 34,976 | -2,241 | 7,385 | 0 |
| 30 Jun 22 | 33,220 | -3,909 | 6,692 | 0 |
| 31 Mar 22 | 30,703 | -4,602 | 6,728 | 0 |
| 31 Dec 21 | 31,127 | -4,425 | 6,636 | 0 |
| 30 Sep 21 | 31,504 | -2,830 | 6,120 | 0 |
| 30 Jun 21 | 32,224 | -543 | 5,817 | 0 |
| 31 Mar 21 | 33,159 | 2,545 | 5,704 | 0 |
| 31 Dec 20 | 30,260 | 28 | 5,359 | 0 |
| 30 Sep 20 | 29,264 | 589 | 5,192 | 0 |
| 30 Jun 20 | 28,480 | 1,266 | 4,906 | 0 |
| 31 Mar 20 | 27,520 | 492 | 4,579 | 0 |
| 31 Dec 19 | 35,828 | 2,859 | 5,872 | 0 |
| 30 Sep 19 | 34,203 | 2,169 | 5,536 | 0 |
| 30 Jun 19 | 32,248 | 745 | 5,346 | 0 |
| 31 Mar 19 | 21,784 | 840 | 3,707 | 0 |
| 31 Dec 18 | 28,547 | -93 | 5,349 | 0 |
| 30 Sep 18 | 28,090 | 139 | 5,420 | 0 |
| 30 Jun 18 | 28,451 | 415 | 4,363 | 0 |
| 31 Mar 18 | 28,451 | 544 | 5,334 | 0 |
| 31 Dec 17 | 35,810 | 1,050 | 6,921 | 0 |
| 30 Sep 17 | 36,593 | 1,124 | 6,931 | 0 |
| 30 Jun 17 | 35,357 | 1,712 | 6,064 | 0 |
| 31 Mar 17 | 27,554 | 2,335 | 4,860 | 0 |
| 31 Dec 16 | 37,237 | 2,840 | 6,984 | 0 |
| 30 Sep 16 | 36,573 | 2,410 | 6,760 | 0 |
| 30 Jun 16 | 34,189 | 2,168 | 6,061 | 0 |
| 31 Mar 16 | 28,622 | 1,317 | 4,026 | 0 |
| 31 Dec 15 | 24,901 | 1,152 | 5,508 | 0 |
| 30 Sep 15 | 12,962 | 860 | 3,367 | 0 |
| 30 Jun 15 | 12,105 | 244 | 3,206 | 0 |
| 31 Mar 15 | 11,958 | 16 | 1,994 | 0 |
| 31 Mar 14 | 10,728 | -1,867 | 2,329 | 0 |
Quality Earnings: 532531 is currently unprofitable.
Growing Profit Margin: 532531 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 532531 is unprofitable, and losses have increased over the past 5 years at a rate of 50.1% per year.
Accelerating Growth: Unable to compare 532531's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 532531 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (23.3%).
Return on Equity
High ROE: 532531 has a negative Return on Equity (-8.66%), as it is currently unprofitable.